RESVERLOGIX
Resverlogix Corporation, a biopharmaceutical company, focuses on the development of novel therapeutics in cardiovascular diseases, as well as in related indications in vascular inflammation and Alzheimer's disease. Its development programs include NexVas Plaque Regression, a technology platform, which has completed a Phase Ia safety trial in humans with RVX-208 and progressed to a Phase Ib/IIa clinical trial for the development of drugs that increase ApoA-I to reduce the risk of cardiovascular d... iseases; NexVas Vascular Inflammation, a discovery stage technology that is in preclinical stages for the development of drugs that target molecular markers of inflammation; NexVas Alzheimer's Disease, a discovery stage technology, which is in Phase I clinical trials for the development of drugs that enhance ApoA-I for the stabilization and regression of Beta Amyloid Plaque; ReVas, a research stage technology for the development of therapeutics to be used with medical devices for the treatment of cardiovascular diseases; and TGF-ß Shield, a preclinical stage therapeutic for the treatment of grievous proliferative diseases, such as cancer and fibrotic conditions. The company is headquartered in Calgary, Canada.
RESVERLOGIX
Industry:
Biopharma Biotechnology Health Care Therapeutics
Founded:
2001-01-01
Address:
Calgary, Alberta, Canada
Country:
Canada
Website Url:
http://www.resverlogix.com
Total Employee:
11+
Status:
Active
Contact:
(403) 254-9252
Email Addresses:
[email protected]
Total Funding:
133.54 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Google Universal Analytics Domain Not Resolving AJAX Libraries API
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Regulus Therapeutics
Regulus Therapeutics is a clinical stage biopharmaceutical company focused on the development and discovery of microRNA therapeutics.
Renovacor
Renovacor is a biopharmaceutical company that focuses on developing transformative gene therapy‑based treatments for cardiovascular disease.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Hepalink
Hepalink investment in Post-IPO Debt - Resverlogix
EFung Capital
EFung Capital investment in Post-IPO Equity - Resverlogix
Citibank
Citibank investment in Post-IPO Debt - Resverlogix
Yorkville Advisors
Yorkville Advisors investment in Post-IPO Equity - Resverlogix
Key Employee Changes
| Date | New article |
|---|---|
| 2022-08-15 | Resverlogix Announces Appointment of New Chief Scientific Officer |
Official Site Inspections
http://www.resverlogix.com
- Host name: 159.203.49.164
- IP address: 159.203.49.164
- Location: Toronto Canada
- Latitude: 43.6547
- Longitude: -79.3623
- Timezone: America/Toronto
- Postal: M5A
More informations about "Resverlogix"
Home - Resverlogix Corp.
Resverlogix is a late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses and providing value-based health solutions to key partners. The …See details»
Overview - Resverlogix Corp.
We provide novel science, clinical and value-based health solutions to key stakeholders such as pharmaceutical, physician, and health payer groups. In 2005, Resverlogix commenced trading …See details»
Resverlogix - Crunchbase Company Profile & Funding
Resverlogix is a biopharmaceutical company, focused on the development of therapeutics in cardiovascular diseases and Alzheimer’s disease. View contacts for Resverlogix to access …See details»
Resverlogix Corp. - LinkedIn
Resverlogix Corp. is a late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses. We provide novel science, clinical and value-based health...See details»
Team - Resverlogix Corp.
Mr. McCaffrey is President and Chief Executive Officer of Resverlogix Corp. He has over 38 years of corporate management experience including over 18 years in drug discovery & …See details»
Resverlogix Corp Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Resverlogix Corp of Calgary, AB. Get the latest business insights from Dun & Bradstreet.See details»
Resverlogix Corp. (TSX: RVX) Company Profile & Overview - Stock …
Nov 15, 2024 · Company profile for Resverlogix Corp. (TSX: RVX) with a description, list of executives, contact details and other key facts.See details»
Resverlogix Company Profile - Office Locations, Competitors, …
Oct 11, 2024 · Resverlogix is a clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses. It is engaged in epigenetics and develops apabetalone, a drug …See details»
Resverlogix - Contacts, Employees, Board Members, Advisors
Resverlogix is a biopharmaceutical company, focused on the development of therapeutics in cardiovascular diseases and Alzheimer’s disease.See details»
RVX | Resverlogix Corp. Profile - MarketWatch
Resverlogix Corp. engages in the research and development of pharmaceutical products for cardiovascular diseases. It develops Apabetalone for diabetes mellitus, chronic kidney, …See details»
2024 Annual & Special Meeting - Resverlogix Corp.
Resverlogix held its annual & special meeting of shareholders on Wednesday, July 31, 2024 at the Roderick Mah Centre for Continuous Learning, Mount Royal University, Calgary, Alberta. …See details»
Resverlogix Corp. - VentureRadar
Website: http://www.resverlogix.com/ Develops apabetalone, a pioneering drug designed to regulate gene expression through inhibiting BET proteins, targeting multiple disease-causing …See details»
Resverlogix - Overview, News & Similar companies - ZoomInfo
Feb 21, 2024 · View Resverlogix (www.resverlogix.com) location in Alberta, Canada , revenue, industry and description. Find related and similar companies as well as employees by title and …See details»
Resverlogix Corp (RVX-T) Stock Price and News
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra …See details»
Resverlogix Corp. (TSX: RVX) Stock Price & Overview - Stock Analysis
2 days ago · Get the latest Resverlogix Corp. (TSX: RVX) stock price quote with financials, statistics, dividends, charts and more.See details»
News - Resverlogix Corp.
Sep 3, 2024 · Resverlogix Announces Voting Results from the 2024 Meeting of Shareholders and Closing of Debenture ExtensionSee details»
Resverlogix Announces Commencement of Patient Enrollment and …
Jan 18, 2022 · Founded in 2001, Resverlogix is a Calgary based late-stage biotechnology company and the world leader in epigenetics, or gene regulation, with the goal of developing …See details»
RVX.TO - | Stock Price & Latest News | Reuters
Nov 19, 2024 · Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of …See details»
Resverlogix Corp. Corporate Presentation
Resverlogix Corp. is a Canadian public company developing an advanced cardiovascular drug called apabetalone. We are pioneering a technology that has the ability to turn multiple …See details»
Resverlogix Corp. (RVX.TO) Stock Price, News, Quote & History
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses.See details»